Clinical outcome following coronary angioplasty in dialysis patients: a case–control study in the era of coronary stenting

C Le Feuvre, G Dambrin, G Helft, F Beygui, M Touam, J P Grünfeld, A Vacheron, J P Metzger

Abstract
Background—Balloon coronary angioplasty has been reported to be ineffective in patients treated for end stage renal disease because of a high restenosis rate.
Objective—To compare the clinical outcome following coronary angioplasty with provisional stenting in dialysis versus non-dialysis patients.
Design—A case–control study.
Patients—Of 1428 consecutive patients who underwent coronary angioplasty, 100 (7%) were being treated for end stage renal disease. These were compared with 100 control patients matched for age, sex, coronary lesions, presence of diabetes mellitus, and rate of coronary stenting (40%).
Main outcome measures—In-hospital and one year clinical outcome.
Results—The rates of procedural success (90% v 93%), in-hospital mortality (1% v 0%), stent thrombosis (0% v 0%), and Q wave myocardial infarction (0% v 1%) were similar in dialysis and non-dialysis patients. One year clinical outcome after coronary angioplasty was similar in the two groups in terms of clinical restenosis (31% v 28%) and myocardial infarction (6% v 2%), but cardiac death was more common in dialysed patients (11% v 2%, p < 0.03).
Conclusions—Dialysis does not increase the risk of clinical restenosis after coronary angioplasty with provisional stenting. Coronary angioplasty is a safe and effective therapeutic procedure in selected dialysis patients with culprit lesions accessible to stenting. However, the one year survival is reduced in this high risk population.

Keywords: renal disease; angioplasty; stents; restenosis

Cardiovascular complications remain the leading cause of mortality among patients with end stage renal disease on haemodialysis. Cardiovascular disease accounts for half the total mortality,1 and myocardial infarction for half the cardiac deaths.2 The overall mortality after myocardial infarction among 34 189 dialysis patients identified from the US Renal Data System database was 59% at one year and 90% at five years.3 Disappointing results have been obtained with balloon coronary angioplasty (PTCA) in these patients, with a high incidence of short and long term complications. Many studies have shown an unfavourable outcome of PTCA compared with coronary artery bypass grafting (CABG) in dialysis patients.4–11 The main reason for this was the high rate of repeat revascularisation for restenosis, which occurs after balloon angioplasty in two thirds of dialysis patients. Thus balloon angioplasty has been reported to be ineffective in dialysis patients.8 12 According to many investigators, coronary bypass surgery is the preferred treatment in dialysis patients with severe angina and extensive coronary artery disease.6 8 12 Whereas coronary stenting has been shown to reduce acute closure and six month restenos- is in non-dialysis patients,13–14 few data on angioplasty and stenting are available in dialysis patients.15 The purpose of the current study was to determine the influence of dialysis on in-hospital and mid-term outcome following coronary angioplasty with provisional stenting. In-hospital and one year clinical outcome were compared between dialysis and control pa- tients matched for clinical and angiographic characteristics.

Methods

STUDY POPULATION
Between January 1995 and April 1999, 1428 patients (1616 coronary lesions) underwent coronary angioplasty at the cardiovascular department of Necker Hospital; 100 patients (7%) had end stage renal disease with dialysis for at least 90 days before the angioplasty. Coronary angioplasty was performed for silent myocardial ischaemia detected before renal transplantation in seven dialysis patients (7%). Baseline clinical and angiographic characteristics, procedural results, and hospital complications were entered prospectively into a computerised database. Dialysis patients were compared with 100 control patients with normal renal function matched for age, sex, coronary lesions, presence of diabetes mellitus, and rate of coronary stenting (40%). Control patients were randomly selected from among 1328 non-dialysis patients. All patients were treated and studied after giving informed consent.

CORONARY ANGIOPLASTY AND STENTING
PTCA was performed using standard tech- niques and supplementary treatment, as de- scribed previously.16 All patients underwent left
Coronary stents and haemodialysis

Table 1 Clinical baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Dialysis patients (n=100)</th>
<th>Non-dialysis patients (n=100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>59 (11)</td>
<td>59 (11)</td>
</tr>
<tr>
<td>Male sex</td>
<td>77%</td>
<td>77%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>82%</td>
<td>37%*</td>
</tr>
<tr>
<td>Smoking history</td>
<td>42%</td>
<td>60%†</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>6.1 (1.3)</td>
<td>5.3 (0.8)†</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.9 (1.5)</td>
<td>1.5 (0.8)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>23%</td>
<td>23%</td>
</tr>
<tr>
<td>Unstable angina</td>
<td>50%</td>
<td>23%</td>
</tr>
<tr>
<td>Prior MI</td>
<td>29%</td>
<td>41%</td>
</tr>
<tr>
<td>Prior CABG</td>
<td>11%</td>
<td>5%</td>
</tr>
<tr>
<td>Medical treatment</td>
<td>62%</td>
<td>66%</td>
</tr>
<tr>
<td>Calcium antagonists</td>
<td>51%</td>
<td>39%</td>
</tr>
<tr>
<td>Nitrates</td>
<td>35%</td>
<td>53%</td>
</tr>
<tr>
<td>Lipid lowering drugs</td>
<td>46%</td>
<td>55%</td>
</tr>
<tr>
<td>Statins</td>
<td>41%</td>
<td>43%</td>
</tr>
</tbody>
</table>

Values are per cent or mean (SD). Dialysis v non-dialysis patients: *p < 0.0001; †p < 0.01.

CABG, coronary artery bypass grafting; MI, myocardial infarction.

ventriculography and coronary angiography in multiple projections. The arterial access route was femoral in all cases. A 6 French guide catheter was used in 65 dialysis patients (65%) and in 62 non-dialysis patients (62%) (NS). A 7 French guide catheter was used in the remaining patients. All patients had been given aspirin 250 mg/day at least three hours before, and a bolus of heparin (100 IU/kg) just before angioplasty.

Stents were inserted either electively, or as a bailout, or following a suboptimal result after balloon angioplasty, with residual stenosis exceeding 30%. The type of stent was similar in dialysis and non-dialysis patients. GFX (AVE), Nir (Scimed), Tenax (Biotronik), Palmaz–Schatz (Johnson and Johnson) stents were implanted in 31%, 27%, 21%, and 10% of the patients, respectively; other tubular or coil stents were used in 8% and 3% of the patients. Procedural success was defined as a diameter stenosis reduction of > 20% with a residual stenosis of < 50% in the absence of major complications (including death, myocardial infarction, and need for emergency surgery). A stent-like result was defined as residual diameter stenosis of < 30%. Myocardial infarction was defined by an increase in serum creatine phosphokinase concentration to more than three times the upper limit of normal, along with the presence of detectable creatine phosphokinase MB isoenzyme. Vascular complications included haematoma requiring a blood transfusion, and false aneurysm requiring surgical repair or prolonged compression. Post-stent antithrombotic treatment included ticlopidine (500 mg/day), started immediately after the procedure and continued for four weeks, and aspirin (100 mg/day for four weeks and then 250 mg/day). Five dialysis and two non-dialysis patients with refractory unstable angina also received abciximab treatment during coronary angioplasty (NS).

ANGIOGRAPHIC ANALYSES

Quantitative angiographic analyses were performed digitally using computer assisted calipers (DCI Philips, CAAS System, Eindhoven, Netherlands). The degree of stenosis before and after angioplasty was measured after intra-coronary injection of Sin-1 (linsidomine, 1 mg) in the view showing the most severe stenosis, and expressed as the minimum lumen diameter and the linear per cent lumen diameter reduction, using the average diameter of the nearest proximal and distal normal segments as the reference.

FOLLOW UP

Long term follow up data were obtained by serial telephone interviews. Late clinical events were corroborated by primary source documentation. Control angiography was restricted to patients with recurrence of limiting symptoms or severe documented ischaemia or both. Restenosis was diagnosed when a narrowing of ≥ 50% of vessel diameter was found at the site of the previous dilatation. Clinical restenosis was defined as recurrent myocardial ischaemia related to angiographic restenosis. The indications for a new revascularisation procedure were either restenosis at a site of previous dilatation or the appearance of a new significant coronary artery stenosis not present on the initial angiogram.

STATISTICAL ANALYSIS

Categorical data are presented as per cent frequencies. Continuous variables are presented as mean (SD). Univariate analyses were performed using the χ² test for categorical data and analysis of variance for continuous variables. Multiple logistic regression and stepwise logistic regression analyses were performed in the standard manner. A probability value of p < 0.05 was considered significant.

Results

CLINICAL AND ANGIOGRAPHIC BASELINE CHARACTERISTICS

Dialysis patients were more often hypertensive and less likely to smoke than non-dialysis patients (table 1). Coronary lesions were similar among the groups, except for calcification which was more common in dialysis patients
Table 3 Procedural results

<table>
<thead>
<tr>
<th></th>
<th>Dialysis patients (n=100)</th>
<th>Non-dialysis patients (n=100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before PTCA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTCA sites (n)</td>
<td>120</td>
<td>120</td>
</tr>
<tr>
<td>Reference diameter (mm)</td>
<td>2.9 (0.5)</td>
<td>3.0 (0.5)</td>
</tr>
<tr>
<td>MLD (mm)</td>
<td>0.8 (0.4)</td>
<td>0.7 (0.4)</td>
</tr>
<tr>
<td>Diameter stenosis (%)</td>
<td>71 (14)</td>
<td>74 (14)</td>
</tr>
<tr>
<td>Lesion length (mm)</td>
<td>11 (5)</td>
<td>11 (6)</td>
</tr>
<tr>
<td>Procedural success</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per patient</td>
<td>90%</td>
<td>93%</td>
</tr>
<tr>
<td>Per lesion</td>
<td>91%</td>
<td>94%</td>
</tr>
<tr>
<td>After successful PTCA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTCA sites (n)</td>
<td>109</td>
<td>113</td>
</tr>
<tr>
<td>MLD (mm)</td>
<td>2.4 (0.6)</td>
<td>2.3 (0.7)</td>
</tr>
<tr>
<td>Diameter stenosis (%)</td>
<td>17 (12)</td>
<td>18 (12)</td>
</tr>
<tr>
<td>Coronary stenting</td>
<td>40%</td>
<td>40%</td>
</tr>
<tr>
<td>Stent length (mm)</td>
<td>11 (3)</td>
<td>13 (6)</td>
</tr>
<tr>
<td>Stent inflation pressure (atm)</td>
<td>11 (2)</td>
<td>12 (3)</td>
</tr>
</tbody>
</table>

Values are mean (SD) or per cent.
MLD, minimum lumen diameter; PTCA, percutaneous transluminal coronary angioplasty.

Discussion

In this study, relative to non-dialysis patients, dialysis patients had: a high and similar procedural success rate; no subacute thrombosis; a similar target vessel revascularisation rate; and a higher cardiac death rate during one year of follow up.

PTCA with Provisional Stenting in Dialysis Patients

In this large series of consecutive patients treated with PTCA, the rate of procedural success was high and similar in dialysis and non-dialysis patients. The rates of death, Q wave myocardial infarction, and urgent repeat revascularisation were low and similar in the two groups. This reflects careful selection of dialysis patients with coronary lesions suitable for angioplasty and accessible to stenting. Our results illustrate the benefits of provisional coronary stenting in patients with suboptimal results after balloon angioplasty. These results are encouraging in comparison with previously reported rates of procedural mortality after balloon angioplasty and bypass surgery in dialysis patients. Herzog identified 5473 patients undergoing balloon angioplasty and 6798 patients undergoing coronary artery bypass surgery from 1978 to 1994 in the US Renal Data System database.4 In-hospital mortality was 5.1% for angioplasty and 14.5% for...
surgery. Similar unfavourable results of balloon angioplasty have been reported in many single centre series, with in-hospital complication rates ranging from 17–43%. The high rate of myocardial infarction after angioplasty in dialysis patients can be explained by the greater likelihood of coronary calcification related to secondary hyperparathyroidism, and by an increased prothrombotic risk leading to fibrin and platelet deposition. Activation of plasma coagulation systems following contact with haemodialysis membranes, and platelet hyper-aggregability with decreased responsiveness to prostacyclin, have been reported in dialysis patients. In our series, only five dialysis patients (5%) received abciximab treatment, whereas coronary angioplasty was performed for unstable angina in half the dialysis patients. A reduced rate of myocardial infarction after angioplasty in dialysis patients may well be obtained by more extensive use of abciximab.

In a review of single centre cardiac surgery series in dialysis patients, Ko and colleagues reported that the operative mortality was between 8% and 9%. Haemorrhagic and infectious complications also occur more often in dialysis patients than in non-dialysis patients.

**CLINICAL RESTENOSIS AFTER ANGIOPLASTY WITH PROVISIONAL STENTING IN DIALYSIS PATIENTS**

In our series the repeat revascularisation rate for restenosis was similar in dialysis and non-dialysis patients. This suggests that dialysis does not affect the clinical restenosis rate when coronary stenting is performed, or when a stent-like result is obtained after balloon angioplasty. The rate was half that reported previously, which has ranged from 47–81%. In the study by Schoebel and colleagues, the six month clinical restenosis rate was 65% in dialysis patients, compared with 37 (9%) following balloon angioplasty (v. 21 (10%) in our study). This suggests that residual stenosis is the main predictive factor of restenosis after PTCA, in accordance with previous studies.

In our study dialysis patients with stent-like results had the same clinical restenosis rate as dialysis patients with coronary stenting. However, owing to the small number of patients, this needs to be confirmed in a larger prospective study. In the Benestent II study (second Belgium-Netherlands stent study), which included non-dialysis patients, stent-like results obtained with balloon angioplasty were less expensive than a strategy of elective stenting, but remain less effective, with a 6% difference in event-free survival. However, our results suggest that PTCA with stent-like results is safe and effective in dialysis patients, and validates the clinical approach we used.

Cardiac deaths during follow up were more common in dialysis patients (11% v 2% in non-dialysis patients). In 1974, Lindner and colleagues suggested that atherogenesis is accelerated in dialysis patients. However, if there is indeed accelerated atherogenesis it does not seem to be secondary to the dialysis itself. Half of all dialysis patients have evidence of coronary artery disease before the initiation of haemodialysis, and no correlation has been found between cardiac events and the duration of dialysis. The high prevalence of coronary artery disease in these patients seems to be related to numerous risk factors for atherosclerosis, including hypertension, diabetes, hyper-coagulation, lipid abnormalities with hypertriglyceridaemia and decreased high density lipoprotein, and hyperhomocystinaemia. In our study the rate of repeat revascularisation for disease progression was similar in dialysis and non-dialysis patients, which could be explained by the intensive treatment of coronary risk factors. The higher rate of cardiac deaths in dialysis patients may be related to cardiac disease linked to renal failure. Cardiac abnormalities in dialysis patients include the following:

- left ventricular hypertrophy explained by hypertension, hypovolaemia, sympathetic overactivity, and anaemia;
- interstitial myocardial fibrosis, related to increased secretion of parathyroid hormone;
- reduced myocardial perfusion reserve, related to structural and functional changes in intramyocardial arteries and to reduced capillary density;
- abnormalities of myocardial metabolism with abnormal control of intracellular calcium in cardiomyocytes, and impaired mitochondrial oxidation and glycolytic pathways.

These microvascular and metabolic abnormalities reduce ischaemia tolerance and increase ventricular arrhythmias and cardiac deaths in dialysis patients, even in the absence of myocardial infarction.

However, our results after coronary stenting in dialysis patients are much better than those reported previously after balloon angioplasty and bypass surgery. In the series of 12,271 revascularised dialysis patients reported by Herzog, the two year mortality was 47.2% for balloon angioplasty and 46.5% for surgery, while the two year cardiac event rate was 83.7% for angioplasty and 70% for surgery (p < 0.0001). Similar unfavourable results with balloon angioplasty and surgery have been reported in many single centre series.

A lower incidence of recurrent angina is reported after surgery, but there are no data to prove that surgery or balloon angioplasty improves survival in dialysis patients. The benefit of coronary stenting in this high risk population was also suggested in a recent report on patients identified in the US Renal Data System database. In this report, dialysis patients had a lower one year mortality after coronary stenting than after bypass surgery or balloon angioplasty performed before stenting facilities became available (80.1%, 68.7%, and 69.4% respectively).

**LIMITATIONS**

The rates of clinical restenosis in dialysis and non-dialysis patients were not significantly different (31% v 28%). However, because of the small number of dialysis patients, there is a risk of β error. As there was no systematic angiographic follow up in patients with
negative non-invasive testing, there may be an underestimation of the angiographic restenosis rate. However, patients with angiographic restenosis but without myocardial ischaemia have the same long term medical care and prognosis as do those without restenosis.21

CONCLUSIONS
Coronary stenting in dialysis patients seems to decrease acute complications following coronary angioplasty with suboptimal results. In our study, dialysis was not a risk factor for clinical restenosis when coronary stenting was performed, or when stent-like results were obtained after balloon angioplasty. Thus coronary angioplasty seems to be a safe and effective therapeutic procedure in selected dialysis patients with culprit lesions accessible to stenting. However, the one year survival is lower in this high risk population. Clinical outcome after angioplasty can be improved by intensive treatment of coronary risk factors and routine non-invasive testing to detect restenosis or disease progression. Bypass surgery should be reserved for dialysis patients with severe angina refractory to medical treatment, extensive coronary artery disease inaccessible to stenting, and an acceptable surgical risk.

Clinical outcome following coronary angioplasty in dialysis patients: a case–control study in the era of coronary stenting

C Le Feuvre, G Dambrin, G Helft, F Beygui, M Touam, J P Grünfeld, A Vacheron and J P Metzger

*Heart* 2001 85: 556-560
doi: 10.1136/heart.85.5.556

Updated information and services can be found at:
http://heart.bmj.com/content/85/5/556

These include:

**References**
This article cites 25 articles, 6 of which you can access for free at:
http://heart.bmj.com/content/85/5/556#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Interventional cardiology (2933)
- Drugs: cardiovascular system (8842)
- Epidemiology (3752)
- Acute coronary syndromes (2742)
- Diabetes (842)
- Metabolic disorders (1030)
- Percutaneous intervention (964)
- Venous thromboembolism (495)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/